Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells 5,209 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the sale, the chief operating officer now owns 91,253 shares in the company, valued at approximately $685,310.03. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Tuesday, November 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.70, for a total value of $40,109.30.

Health Catalyst Price Performance

Health Catalyst stock opened at $6.89 on Friday. The stock has a market cap of $419.24 million, a price-to-earnings ratio of -5.10 and a beta of 1.36. The firm has a 50-day moving average of $7.79 and a two-hundred day moving average of $7.53. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same period last year, the company earned ($0.22) EPS. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, research analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on HCAT. Royal Bank of Canada raised their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Citigroup reduced their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.45.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC lifted its position in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the period. Impax Asset Management Group plc lifted its holdings in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares during the period. Millennium Management LLC boosted its position in Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after acquiring an additional 25,000 shares during the period. Finally, Daventry Group LP raised its position in shares of Health Catalyst by 3.9% in the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after acquiring an additional 84,178 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.